Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

2.120 -0.070 (-3.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 454,083
Open 2.180
Bid (Size) 2.070 (1)
Ask (Size) 2.180 (1)
Prev. Close 2.190
Today's Range 2.050 - 2.270
52wk Range 1.835 - 41.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alzamend Neuro Issues Letter to Stockholders
From Alzamend Neuro
Via Business Wire
Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-76.96%
-76.96%
1 Month
+1.44%
+1.44%
3 Month
-63.45%
-63.45%
6 Month
-82.03%
-82.03%
1 Year
-94.76%
-94.76%

More News

Read More
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Via PressReach
Exposures Product Safety
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Via Benzinga
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Via News Direct
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
Via News Direct
Exposures Product Safety
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Via PressReach
Exposures Product Safety
Headline
Via News Direct
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
Via PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
Via Benzinga
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.